- Approval Id
- 085930da449edc0c
- Drug Approval Emc Name
- Physioneal 35 Glucose 2.27% w/v / 22.7 mg/ml Clear-Flex, Solution for peritoneal dialysis.
- Drug Name
- Physioneal 35 Glucose 2.27% w/v / 22.7 mg/ml Clear-Flex, Solution for peritoneal dialysis.
- Company Name
- Vantive Limited
- Company Address
- Wavertree Technology Park, 2 Wavertree Boulevard, Liverpool, L7 9PE
- Company Website
- //www.vantive.com
- Company Telephone
- 0151 250 1560
- Company Medical Info Direct Line
- 0151 250 1560
- Company Medical Info Email
- medical.information.uki@vantive.com
- Company Customer Care Direct Line
- 0800 023 4002
- Atc Code
- B05DB
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Vantive Limited
Wavertree Technology Park
2 Wavertree Boulevard
Liverpool, L7 9PE
United Kingdom
- Authorisation Number
- PL 58711/0011
- Authorisation Date
- Date of first authorisation: 5 October 2007
Date of latest renewal: 23 October 2008
- Instruction Authorisation Holder
- Vantive Limited
Wavertree Technology Park
2 Wavertree Boulevard
Liverpool, L7 9PE
United Kingdom
- Instruction Authorisation Number
- PL 58711/0011
- Instruction Authorisation Date
- Date of first authorisation: 5 October 2007
Date of latest renewal: 23 October 2008
- Instruction Dosage Form
- Solution for peritoneal dialysis.
Sterile, clear, colourless solution.
The pH of the final solution is 7.4.
Osmolarity 396 mOsmol/l
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
PHYSIONEAL 35 is indicated whenever peritoneal dialysis is employed, including:
• Acute and chronic renal failure;
• Severe water retention;
• Severe electrolyte imbalance;
• Drug intoxication with dialysable substances, when a more adequate therapeutic alternative is not available.
PHYSIONEAL 35 hydrogen carbonate/lactatebased peritoneal dialysis solutions with a physiological pH are particularly indicated in patients in whom solutions based on lactate buffer only, with a low pH, cause abdominal inflow pain or discomfort.4.2 Posology and method of administration
Posology
The mode of therapy, frequency of treatment, exchange volume, duration of dwell and length of dialysis should be selected by the physician.
To avoid the risk of severe dehydration, hypovolaemia and to minimise the loss of proteins, it is advisable to select the peritoneal dialysis solution with the lowest osmolarity consistent with fluid removal requirements for each exchange.
\*Adults\*
Patients on continuous ambulatory peritoneal dialysis (CAPD) typically perform 4 cycles per day (24 hours). Patients on automated peritoneal dialysis (APD) typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size, usually from 2.0 to 2.5 litres.
\*Elderly\*
As for adults.
\*Paediatric population\*
The safety and efficacy of PHYSIONEAL 35 in paediatric patients have not been established. Therefore the clinical benefits of PHYSIONEAL 35 have to be balanced versus the risks of side effects in this patient category.
The use of PHYSIONEAL 35 in the \*\*Clear-Flex container\*\* is not recommended in children requiring a fill volume < 1600 ml due to the risk of not detecting a possible misinfusion (administration of the small chamber only). See section 4.4.
Method of administration
\*Precautions to be taken before handling or administering the medicinal product\*
• PHYSIONEAL 35 is intended for intraperitoneal administration only. Not for intravenous administration.
• Peritoneal dialysis solutions may be warmed to 37°C to enhance patient comfort. However, only dry heat (for example, heating pad, warming plate) should be used. Solutions should not be heated in water or in a microwave oven due to the potential for patient injury or discomfort.
• Aseptic technique should be employed throughout the peritoneal dialysis procedure.
• Do not administer if the solution is discoloured, cloudy, contains particulate matter, shows evidence of leakage between chambers or to the exterior, or if seals are not intact.
• The drained fluid should be inspected for the presence of fibrin or cloudiness, which may indicate the presence of peritonitis.
• For single use only.
• After removal of the overpouch, immediately open the long-seal (interchamber seal) to mix the two solutions and then open the short SafetyMoon seal (access seal) to allow administration of the mixed solution. The intraperitoneal solution must be infused within 24 hours after mixing.
• For instructions on the use of the medicinal product see section 6.6 Special precautions for disposal and other handling.4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
PHYSIONEAL 35 should not be used in patients with:
• uncorrectable mechanical defects that prevent effective PD or increase the risk of infection,
• documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.4.4 Special warnings and precautions for use
Use in patients with abdominal conditions
Peritoneal dialysis should be done with caution in patients with:
1) abdominal conditions, including disruption of the peritoneal membrane and diaphragm by surgery, from congenital anomalies or trauma until healing is complete, abdominal tumors, abdominal wall infection, hernias, fecal fistula, colostomy or iliostomy, frequent episodes of diverticulitis, inflammatory or ischemic bowel disease, large polycystic kidneys, or other conditions that compromise the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity
2) other conditions including recent aortic graft replacement and severe pulmonary disease.
Encapsulating Peritoneal Sclerosis (EPS)
Encapsulating Peritoneal Sclerosis (EPS) is considered to be a known, rare complication of peritoneal dialysis therapy. EPS has been reported in patients using peritoneal dialysis solutions including some patients using PHYSIONEAL 35 as part of their PD therapy.
Peritonitis
If peritonitis occurs, the choice and dosage of antibiotics should be based upon the results of identification and sensitivity studies of the isolated organism(s) when possible. Prior to identification of the involved organism(s), broad-spectrum antibiotics may be indicated.
Hypersensitivity
Solutions containing glucose derived from hydrolysed maize starch should be used with caution in patients with a known allergy to maize or maize products. Hypersensitivity reactions such as those due to a corn (maize) starch allergy, including anaphylactic/anaphylactoid reactions, may occur. Stop the infusion immediately and drain the solution from the peritoneal cavity if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Use in patients with elevated lactate levels
Patients with elevated lactate levels should use lactate-containing peritoneal dialysis solutions with caution. It is recommended that patients with conditions known to increase the risk of lactic acidosis [e.g., severe hypotension, sepsis, acute renal failure, inborn errors of metabolism, treatment with drugs such as metformin and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] must be monitored for occurrence of lactic acidosis before the start of treatment and during treatment with lactate-based peritoneal dialysis solutions.
General monitoring
When prescribing the solution to be used for an individual patient, consideration should be given to the potential interaction between the dialysis treatment and therapy directed at other existing illnesses. Serum potassium levels should be monitored carefully in patients treated with cardiac glycosides.
An accurate fluid balance record must be kept and the body weight of the patient must carefully be monitored to avoid over- or underhydration with severe consequences including congestive heart failure, volume depletion and shock.
Protein, amino acids, water soluble vitamins and other medicines may be lost during peritoneal dialysis and may require replacement.
Serum electrolyte concentrations (particularly hydrogen carbonate, potassium, magnesium, calcium and phosphate), blood chemistry (including parathyroid hormone and lipid parameters) and haematological parameters should be monitored periodically.
Metabolic alkalosis
In patients with plasma hydrogen carbonate level above 30 mmol/l, the risk of possible metabolic alkalosis should be weighed against the benefits of treatment with this product.
Overinfusion
Overinfusion of PHYSIONEAL 35 solutions into the peritoneal cavity may be characterized by abdominal distension/abdominal pain and/or shortness of breath.
Treatment of PHYSIONEAL 35 overinfusion is to drain the solution from the peritoneal cavity.
Use of higher glucose concentrations
Excessive use of PHYSIONEAL 35 peritoneal dialysis solution with a higher dextrose (glucose) during a peritoneal dialysis treatment may result in excessive removal of water from the patient. See section 4.9.
Addition of potassium
Potassium is omitted from PHYSIONEAL 35 solutions due to the risk of hyperkalemia.
In situations in which there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/l) may be indicated to prevent severe hypokalemia and should be made after careful evaluation of serum and total body potassium, only under the direction of a physician.
Use in diabetic patients
In patients with diabetes, blood glucose levels should be monitored and the dosage of insulin or other treatment for hyperglycaemia should be adjusted.
Improper administration
Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, which may result in abdominal pain and/or peritonitis.
Patients must be instructed to open both the long and the short seals prior to infusion. If only the short SafetyMoon seal opens, infusion of the unmixed solution can cause abdominal pain, hypernatremia and severe metabolic alkalosis. In case of infusion of unmixed solution, the patient should immediately drain the solution and use a newly mixed bag.
Paediatric population
Safety and efficacy in paediatric patients have not been established.4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
• Blood concentration of dialysable medicinal product may be reduced during dialysis. A possible compensation for losses must be taken into consideration.
• Plasma levels of potassium in patients using cardiac glycosides must be carefully monitored as there is a risk of digitalis intoxication. Potassium supplements may be necessary.4.6 Fertility, pregnancy and lactation
Pregnancy
There are no or limited amount of data from the use of PHYSIONEAL 35 in pregnant women.
PHYSIONEAL 35 is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding
It is unknown whether PHYSIONEAL 35 metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PHYSIONEAL 35 therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
There are no clinical data on fertility.4.7 Effects on ability to drive and use machines
End stage renal disease (ESRD) patients undergoing peritoneal dialysis may experience undesirable effects, which could affect the ability to drive or use machines.4.8 Undesirable effects
Adverse reactions (occurring in 1% of patients or more) from the clinical trials and post marketing are listed below.
The adverse drug reactions listed in this section are given following the recommended frequency convention: very common: (≥1/10); common: (≥1/100 to <1/10) ; uncommon: (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) ; very rare (<1/10,000), not known (cannot be estimated from the available data)
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | | \*\*Preferred Term\*\* | | \*\*Frequency\*\* | |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS | | Eosinophilia | | Not known | |
| METABOLISM AND NUTRITION DISORDERS | | Hypokalaemia Fluid retention Hypercalcaemia Hypervolaemia Anorexia Dehydration Hyperglycaemia Lactic Acidosis | | Common Common Common Uncommon Uncommon Uncommon Uncommon Uncommon | |
| PSYCHIATRIC DISORDERS | | Insomnia | | Uncommon | |
| NERVOUS SYSTEM DISORDERS | | Dizziness Headache | | Uncommon Uncommon | |
| VASCULAR DISORDERS | | Hypertension Hypotension | | Common Uncommon | |
| RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS | | Dyspnoea Cough | | Uncommon Uncommon | |
| GASTROINTESTINAL DISORDERS | | Peritonitis Peritoneal membrane failure Abdominal pain Dyspepsia Flatulence Nausea Sclerosing encapsulating peritonitis Cloudy peritoneal effluent | | Common Uncommon Uncommon Uncommon Uncommon Uncommon Not known Not known | |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | | Angioedema Rash | | Not known Not known | |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | | Musculoskeletal pain | | Not known | |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | | Oedema Asthenia Chills Facial oedema Hernia Malaise Thirst Pyrexia | | Common Common Uncommon Uncommon Uncommon Uncommon Uncommon Not known | |
| INVESTIGATIONS | | Weight increased PCO2 increased | | Common Uncommon | |
Other undesirable effects of peritoneal dialysis related to the procedure: bacterial peritonitis, catheter site infection, catheter related complication.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/ risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard.4.9 Overdose
Possible consequences of overdose include hypervolaemia, hypovolaemia, electrolyte disturbances or (in diabetic patients) hyperglycaemia. See section 4.4.
Management of overdose
Hypervolaemia may be managed by using hypertonic peritoneal dialysis solutions and fluid restriction.
Hypovolaemia may be managed by fluid replacement either orally or intravenously, depending on the degree of dehydration.
Electrolyte disturbances shall be managed according to the specific electrolyte disturbance verified by blood test. The most probable disturbance, hypokalaemia, may be managed by the oral ingestion of potassium or by the addition of potassium chloride in the peritoneal dialysis solution prescribed by the treating physician.
Hyperglycaemia (in diabetic patients) shall be managed by adjusting the insulin dose according to the insulin scheme prescribed by the treating physician.
See section 4.4 for information on overinfusion of Physioneal 35 and its treatment.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Peritoneal Dialytics, Hypertonic solutions
ATC code: B05DB
Mechanism of action
For patients with renal failure, peritoneal dialysis is a procedure for removing toxic substances produced by nitrogen metabolism and normally excreted by the kidneys, and for aiding the regulation of fluid and electrolyte as well as acid base balances.
This procedure is accomplished by administering peritoneal dialysis fluid through a catheter into the peritoneal cavity.
Pharmacodynamic effects
Glucose produces a solution hyperosmolar to the plasma, creating an osmotic gradient which facilitates fluid removal from the plasma to the solution. Transfer of substances between the patient's peritoneal capillaries and the dialysis fluid is made across the peritoneal membrane according to the principles of osmosis and diffusion. After dwell time, the solution is saturated with toxic substances and must be changed. With the exception of lactate, present as a hydrogen carbonate precursor, electrolyte concentrations in the fluid have been formulated in an attempt to normalise plasma electrolyte concentrations. Nitrogenous waste products, present in high concentration in the blood, cross the peritoneal membrane into the dialysis fluid.
Clinical efficacy and safety
More than 30% of the patients in the clinical trials were older than 65. The evaluation of the results obtained for this group does not show any difference to the rest of the patients.
\*In vitro\* and \*ex vivo\* studies have shown evidence of improved biocompatibility indicators of PHYSIONEAL 35 in comparison with standard lactate buffered solution. In addition, clinical studies in limited numbers of patients with abdominal inflow pain have confirmed some symptomatic benefit. To date, however, there are no data available which indicate that clinical complications overall are reduced or that regular use of such solutions might translate into meaningful benefits over the longer-term.5.2 Pharmacokinetic properties
Intraperitoneally administered glucose, electrolytes and water are absorbed into the blood and metabolised by the usual pathways.
Glucose is metabolised (1 g of glucose = 4 kilocalories or 17 kilojoules) into CO2 and H2O.5.3 Preclinical safety data
No non-clinical studies have been performed with PHYSIONEAL 35.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Hydrochloric acid dilute (pH adjuster)
Sodium hydroxide (pH adjuster)
Water for Injections.6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.3.
Aminoglycosides (eg. netilmycin, gentamycin, tobramycin) should not be mixed with penicillins due to chemical incompatibility.6.3 Shelf life
2 years.
After opening / dilution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C for: cefazolin (750 mg/l), heparin (2500 IU/L), low molecular weight heparin (Innohep 2500 IU/L), netilmycin (60 mg/l) and vancomycin (1000 mg/l).
Chemical and physical in-use stability has been demonstrated for 6 hours at 25°C for insulin (Actrapid 4 IU/L, 10 IU/L, 20 IU/L and 40 IU/L).
Gentamicin (60 mg/l) and tobramycin (60 mg/l) can be added if the solution is used immediately after drug addition.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours, unless reconstitution / dilution (etc) has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
Do not store below 4°C.
For storage conditions of the reconstituted medicinal product, see section 6.3.6.5 Nature and contents of container
The PHYSIONEAL 35 solution is stored inside a two-chamber bag made of a coextruded film (Clear-Flex film) of Polypropylene, Polyamide and a blend of Polypropylene, SEBS and Polyethylene.
On the upper chamber an injection site is welded for drug admixture to the glucose with electrolytes solution. On the lower chamber a valve system is welded for connection to a suitable administration set allowing dialysis operations.
The bag is wrapped inside a transparent overpouch made of multilayer copolymers.
Container volumes after reconstitution: 1500 ml (1125 ml of solution A and 375 ml of solution B), 2000 ml (1500 ml of solution A and 500 ml of solution B), 2500 ml (1875 ml of solution A and 625 ml of solution B), 3000 ml (2250 ml of solution A and 750 ml of solution B), 4500 ml (3375 ml of solution A and 1125 ml of solution B), 5000 ml (3750 ml of solution A and 1250 ml of solution B).
The single bag is a two-chamber bag (large chamber "A" and small chamber "B", see section 2) to be used in Automated Peritoneal Dialysis. The twin bag is a two-chamber bag (large chamber "A" and small chamber "B", see section 2) with an integrated disconnect system plus an empty drain bag to be used in Continuous Ambulatory Peritoneal Dialysis.
Not all pack sizes may be marketed:
| | | | |
| --- | --- | --- | --- |
| 1.5 l 1.5 l 1.5 l 1.5 l | 5 units per box 6 units per box 5 units per box 6 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 2.0 l 2.0 l 2.0 l 2.0 l | 4 units per box 5 units per box 4 units per box 5 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 2.5 l 2.5 l 2.5 l 2.5 l | 3 units per box 4 units per box 3 units per box 4 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 3.0 l 3.0 l | 3 units per box 3 units per box | two-chamber single bag two-chamber twin bag | Luer connector Luer connector |
| 4.5 l | 2 units per box | two-chamber single bag | Luer connector |
| 5.0 l 5.0 l | 2 units per box 2 units per box | two-chamber single bag single two-chamber bag | Luer connector Luer connector + HomeChoice APD set with Luer connector + clamshell and minicap |6.6 Special precautions for disposal and other handling
For details on the conditions of administration see section 4.2.
• Detailed instruction on the Peritoneal Dialysis exchange procedure is given to patients by means of training, in a specialised training centre, prior to home use.
• After removal of the overpouch, immediately open the long-seal (interchamber seal) to mix the two solutions and then open the short Safety Moon seal (access seal) to allow administration of the mixed solution. The intraperitoneal solution must be infused within 24 hours after mixing. See section 4.2.
• Drugs should be added through the medication site in the larger chamber before opening the interchamber peel-seal. Drug compatibility must be checked before admixture and the pH and salts of the solution must be taken into account. The product should be used immediately after any drug addition.
• Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
• In the case of damage, the container should be discarded.
• The solution is free from bacterial endotoxins.
- Instruction Content
- ## Pharmaceutical Form
Solution for peritoneal dialysis.
Sterile, clear, colourless solution.
The pH of the final solution is 7.4.
Osmolarity 396 mOsmol/l
## Clinical Particulars
4.1 Therapeutic indications
PHYSIONEAL 35 is indicated whenever peritoneal dialysis is employed, including:
• Acute and chronic renal failure;
• Severe water retention;
• Severe electrolyte imbalance;
• Drug intoxication with dialysable substances, when a more adequate therapeutic alternative is not available.
PHYSIONEAL 35 hydrogen carbonate/lactatebased peritoneal dialysis solutions with a physiological pH are particularly indicated in patients in whom solutions based on lactate buffer only, with a low pH, cause abdominal inflow pain or discomfort.4.2 Posology and method of administration
Posology
The mode of therapy, frequency of treatment, exchange volume, duration of dwell and length of dialysis should be selected by the physician.
To avoid the risk of severe dehydration, hypovolaemia and to minimise the loss of proteins, it is advisable to select the peritoneal dialysis solution with the lowest osmolarity consistent with fluid removal requirements for each exchange.
\*Adults\*
Patients on continuous ambulatory peritoneal dialysis (CAPD) typically perform 4 cycles per day (24 hours). Patients on automated peritoneal dialysis (APD) typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size, usually from 2.0 to 2.5 litres.
\*Elderly\*
As for adults.
\*Paediatric population\*
The safety and efficacy of PHYSIONEAL 35 in paediatric patients have not been established. Therefore the clinical benefits of PHYSIONEAL 35 have to be balanced versus the risks of side effects in this patient category.
The use of PHYSIONEAL 35 in the \*\*Clear-Flex container\*\* is not recommended in children requiring a fill volume < 1600 ml due to the risk of not detecting a possible misinfusion (administration of the small chamber only). See section 4.4.
Method of administration
\*Precautions to be taken before handling or administering the medicinal product\*
• PHYSIONEAL 35 is intended for intraperitoneal administration only. Not for intravenous administration.
• Peritoneal dialysis solutions may be warmed to 37°C to enhance patient comfort. However, only dry heat (for example, heating pad, warming plate) should be used. Solutions should not be heated in water or in a microwave oven due to the potential for patient injury or discomfort.
• Aseptic technique should be employed throughout the peritoneal dialysis procedure.
• Do not administer if the solution is discoloured, cloudy, contains particulate matter, shows evidence of leakage between chambers or to the exterior, or if seals are not intact.
• The drained fluid should be inspected for the presence of fibrin or cloudiness, which may indicate the presence of peritonitis.
• For single use only.
• After removal of the overpouch, immediately open the long-seal (interchamber seal) to mix the two solutions and then open the short SafetyMoon seal (access seal) to allow administration of the mixed solution. The intraperitoneal solution must be infused within 24 hours after mixing.
• For instructions on the use of the medicinal product see section 6.6 Special precautions for disposal and other handling.4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
PHYSIONEAL 35 should not be used in patients with:
• uncorrectable mechanical defects that prevent effective PD or increase the risk of infection,
• documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.4.4 Special warnings and precautions for use
Use in patients with abdominal conditions
Peritoneal dialysis should be done with caution in patients with:
1) abdominal conditions, including disruption of the peritoneal membrane and diaphragm by surgery, from congenital anomalies or trauma until healing is complete, abdominal tumors, abdominal wall infection, hernias, fecal fistula, colostomy or iliostomy, frequent episodes of diverticulitis, inflammatory or ischemic bowel disease, large polycystic kidneys, or other conditions that compromise the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity
2) other conditions including recent aortic graft replacement and severe pulmonary disease.
Encapsulating Peritoneal Sclerosis (EPS)
Encapsulating Peritoneal Sclerosis (EPS) is considered to be a known, rare complication of peritoneal dialysis therapy. EPS has been reported in patients using peritoneal dialysis solutions including some patients using PHYSIONEAL 35 as part of their PD therapy.
Peritonitis
If peritonitis occurs, the choice and dosage of antibiotics should be based upon the results of identification and sensitivity studies of the isolated organism(s) when possible. Prior to identification of the involved organism(s), broad-spectrum antibiotics may be indicated.
Hypersensitivity
Solutions containing glucose derived from hydrolysed maize starch should be used with caution in patients with a known allergy to maize or maize products. Hypersensitivity reactions such as those due to a corn (maize) starch allergy, including anaphylactic/anaphylactoid reactions, may occur. Stop the infusion immediately and drain the solution from the peritoneal cavity if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Use in patients with elevated lactate levels
Patients with elevated lactate levels should use lactate-containing peritoneal dialysis solutions with caution. It is recommended that patients with conditions known to increase the risk of lactic acidosis [e.g., severe hypotension, sepsis, acute renal failure, inborn errors of metabolism, treatment with drugs such as metformin and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] must be monitored for occurrence of lactic acidosis before the start of treatment and during treatment with lactate-based peritoneal dialysis solutions.
General monitoring
When prescribing the solution to be used for an individual patient, consideration should be given to the potential interaction between the dialysis treatment and therapy directed at other existing illnesses. Serum potassium levels should be monitored carefully in patients treated with cardiac glycosides.
An accurate fluid balance record must be kept and the body weight of the patient must carefully be monitored to avoid over- or underhydration with severe consequences including congestive heart failure, volume depletion and shock.
Protein, amino acids, water soluble vitamins and other medicines may be lost during peritoneal dialysis and may require replacement.
Serum electrolyte concentrations (particularly hydrogen carbonate, potassium, magnesium, calcium and phosphate), blood chemistry (including parathyroid hormone and lipid parameters) and haematological parameters should be monitored periodically.
Metabolic alkalosis
In patients with plasma hydrogen carbonate level above 30 mmol/l, the risk of possible metabolic alkalosis should be weighed against the benefits of treatment with this product.
Overinfusion
Overinfusion of PHYSIONEAL 35 solutions into the peritoneal cavity may be characterized by abdominal distension/abdominal pain and/or shortness of breath.
Treatment of PHYSIONEAL 35 overinfusion is to drain the solution from the peritoneal cavity.
Use of higher glucose concentrations
Excessive use of PHYSIONEAL 35 peritoneal dialysis solution with a higher dextrose (glucose) during a peritoneal dialysis treatment may result in excessive removal of water from the patient. See section 4.9.
Addition of potassium
Potassium is omitted from PHYSIONEAL 35 solutions due to the risk of hyperkalemia.
In situations in which there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/l) may be indicated to prevent severe hypokalemia and should be made after careful evaluation of serum and total body potassium, only under the direction of a physician.
Use in diabetic patients
In patients with diabetes, blood glucose levels should be monitored and the dosage of insulin or other treatment for hyperglycaemia should be adjusted.
Improper administration
Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, which may result in abdominal pain and/or peritonitis.
Patients must be instructed to open both the long and the short seals prior to infusion. If only the short SafetyMoon seal opens, infusion of the unmixed solution can cause abdominal pain, hypernatremia and severe metabolic alkalosis. In case of infusion of unmixed solution, the patient should immediately drain the solution and use a newly mixed bag.
Paediatric population
Safety and efficacy in paediatric patients have not been established.4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
• Blood concentration of dialysable medicinal product may be reduced during dialysis. A possible compensation for losses must be taken into consideration.
• Plasma levels of potassium in patients using cardiac glycosides must be carefully monitored as there is a risk of digitalis intoxication. Potassium supplements may be necessary.4.6 Fertility, pregnancy and lactation
Pregnancy
There are no or limited amount of data from the use of PHYSIONEAL 35 in pregnant women.
PHYSIONEAL 35 is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding
It is unknown whether PHYSIONEAL 35 metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PHYSIONEAL 35 therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
There are no clinical data on fertility.4.7 Effects on ability to drive and use machines
End stage renal disease (ESRD) patients undergoing peritoneal dialysis may experience undesirable effects, which could affect the ability to drive or use machines.4.8 Undesirable effects
Adverse reactions (occurring in 1% of patients or more) from the clinical trials and post marketing are listed below.
The adverse drug reactions listed in this section are given following the recommended frequency convention: very common: (≥1/10); common: (≥1/100 to <1/10) ; uncommon: (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) ; very rare (<1/10,000), not known (cannot be estimated from the available data)
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | | \*\*Preferred Term\*\* | | \*\*Frequency\*\* | |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS | | Eosinophilia | | Not known | |
| METABOLISM AND NUTRITION DISORDERS | | Hypokalaemia Fluid retention Hypercalcaemia Hypervolaemia Anorexia Dehydration Hyperglycaemia Lactic Acidosis | | Common Common Common Uncommon Uncommon Uncommon Uncommon Uncommon | |
| PSYCHIATRIC DISORDERS | | Insomnia | | Uncommon | |
| NERVOUS SYSTEM DISORDERS | | Dizziness Headache | | Uncommon Uncommon | |
| VASCULAR DISORDERS | | Hypertension Hypotension | | Common Uncommon | |
| RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS | | Dyspnoea Cough | | Uncommon Uncommon | |
| GASTROINTESTINAL DISORDERS | | Peritonitis Peritoneal membrane failure Abdominal pain Dyspepsia Flatulence Nausea Sclerosing encapsulating peritonitis Cloudy peritoneal effluent | | Common Uncommon Uncommon Uncommon Uncommon Uncommon Not known Not known | |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | | Angioedema Rash | | Not known Not known | |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | | Musculoskeletal pain | | Not known | |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | | Oedema Asthenia Chills Facial oedema Hernia Malaise Thirst Pyrexia | | Common Common Uncommon Uncommon Uncommon Uncommon Uncommon Not known | |
| INVESTIGATIONS | | Weight increased PCO2 increased | | Common Uncommon | |
Other undesirable effects of peritoneal dialysis related to the procedure: bacterial peritonitis, catheter site infection, catheter related complication.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/ risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard.4.9 Overdose
Possible consequences of overdose include hypervolaemia, hypovolaemia, electrolyte disturbances or (in diabetic patients) hyperglycaemia. See section 4.4.
Management of overdose
Hypervolaemia may be managed by using hypertonic peritoneal dialysis solutions and fluid restriction.
Hypovolaemia may be managed by fluid replacement either orally or intravenously, depending on the degree of dehydration.
Electrolyte disturbances shall be managed according to the specific electrolyte disturbance verified by blood test. The most probable disturbance, hypokalaemia, may be managed by the oral ingestion of potassium or by the addition of potassium chloride in the peritoneal dialysis solution prescribed by the treating physician.
Hyperglycaemia (in diabetic patients) shall be managed by adjusting the insulin dose according to the insulin scheme prescribed by the treating physician.
See section 4.4 for information on overinfusion of Physioneal 35 and its treatment.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Peritoneal Dialytics, Hypertonic solutions
ATC code: B05DB
Mechanism of action
For patients with renal failure, peritoneal dialysis is a procedure for removing toxic substances produced by nitrogen metabolism and normally excreted by the kidneys, and for aiding the regulation of fluid and electrolyte as well as acid base balances.
This procedure is accomplished by administering peritoneal dialysis fluid through a catheter into the peritoneal cavity.
Pharmacodynamic effects
Glucose produces a solution hyperosmolar to the plasma, creating an osmotic gradient which facilitates fluid removal from the plasma to the solution. Transfer of substances between the patient's peritoneal capillaries and the dialysis fluid is made across the peritoneal membrane according to the principles of osmosis and diffusion. After dwell time, the solution is saturated with toxic substances and must be changed. With the exception of lactate, present as a hydrogen carbonate precursor, electrolyte concentrations in the fluid have been formulated in an attempt to normalise plasma electrolyte concentrations. Nitrogenous waste products, present in high concentration in the blood, cross the peritoneal membrane into the dialysis fluid.
Clinical efficacy and safety
More than 30% of the patients in the clinical trials were older than 65. The evaluation of the results obtained for this group does not show any difference to the rest of the patients.
\*In vitro\* and \*ex vivo\* studies have shown evidence of improved biocompatibility indicators of PHYSIONEAL 35 in comparison with standard lactate buffered solution. In addition, clinical studies in limited numbers of patients with abdominal inflow pain have confirmed some symptomatic benefit. To date, however, there are no data available which indicate that clinical complications overall are reduced or that regular use of such solutions might translate into meaningful benefits over the longer-term.5.2 Pharmacokinetic properties
Intraperitoneally administered glucose, electrolytes and water are absorbed into the blood and metabolised by the usual pathways.
Glucose is metabolised (1 g of glucose = 4 kilocalories or 17 kilojoules) into CO2 and H2O.5.3 Preclinical safety data
No non-clinical studies have been performed with PHYSIONEAL 35.
## Pharmaceutical Particulars
6.1 List of excipients
Hydrochloric acid dilute (pH adjuster)
Sodium hydroxide (pH adjuster)
Water for Injections.6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.3.
Aminoglycosides (eg. netilmycin, gentamycin, tobramycin) should not be mixed with penicillins due to chemical incompatibility.6.3 Shelf life
2 years.
After opening / dilution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C for: cefazolin (750 mg/l), heparin (2500 IU/L), low molecular weight heparin (Innohep 2500 IU/L), netilmycin (60 mg/l) and vancomycin (1000 mg/l).
Chemical and physical in-use stability has been demonstrated for 6 hours at 25°C for insulin (Actrapid 4 IU/L, 10 IU/L, 20 IU/L and 40 IU/L).
Gentamicin (60 mg/l) and tobramycin (60 mg/l) can be added if the solution is used immediately after drug addition.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours, unless reconstitution / dilution (etc) has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
Do not store below 4°C.
For storage conditions of the reconstituted medicinal product, see section 6.3.6.5 Nature and contents of container
The PHYSIONEAL 35 solution is stored inside a two-chamber bag made of a coextruded film (Clear-Flex film) of Polypropylene, Polyamide and a blend of Polypropylene, SEBS and Polyethylene.
On the upper chamber an injection site is welded for drug admixture to the glucose with electrolytes solution. On the lower chamber a valve system is welded for connection to a suitable administration set allowing dialysis operations.
The bag is wrapped inside a transparent overpouch made of multilayer copolymers.
Container volumes after reconstitution: 1500 ml (1125 ml of solution A and 375 ml of solution B), 2000 ml (1500 ml of solution A and 500 ml of solution B), 2500 ml (1875 ml of solution A and 625 ml of solution B), 3000 ml (2250 ml of solution A and 750 ml of solution B), 4500 ml (3375 ml of solution A and 1125 ml of solution B), 5000 ml (3750 ml of solution A and 1250 ml of solution B).
The single bag is a two-chamber bag (large chamber "A" and small chamber "B", see section 2) to be used in Automated Peritoneal Dialysis. The twin bag is a two-chamber bag (large chamber "A" and small chamber "B", see section 2) with an integrated disconnect system plus an empty drain bag to be used in Continuous Ambulatory Peritoneal Dialysis.
Not all pack sizes may be marketed:
| | | | |
| --- | --- | --- | --- |
| 1.5 l 1.5 l 1.5 l 1.5 l | 5 units per box 6 units per box 5 units per box 6 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 2.0 l 2.0 l 2.0 l 2.0 l | 4 units per box 5 units per box 4 units per box 5 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 2.5 l 2.5 l 2.5 l 2.5 l | 3 units per box 4 units per box 3 units per box 4 units per box | two-chamber single bag two-chamber single bag two-chamber twin bag two-chamber twin bag | Luer connector Luer connector Luer connector Luer connector |
| 3.0 l 3.0 l | 3 units per box 3 units per box | two-chamber single bag two-chamber twin bag | Luer connector Luer connector |
| 4.5 l | 2 units per box | two-chamber single bag | Luer connector |
| 5.0 l 5.0 l | 2 units per box 2 units per box | two-chamber single bag single two-chamber bag | Luer connector Luer connector + HomeChoice APD set with Luer connector + clamshell and minicap |6.6 Special precautions for disposal and other handling
For details on the conditions of administration see section 4.2.
• Detailed instruction on the Peritoneal Dialysis exchange procedure is given to patients by means of training, in a specialised training centre, prior to home use.
• After removal of the overpouch, immediately open the long-seal (interchamber seal) to mix the two solutions and then open the short Safety Moon seal (access seal) to allow administration of the mixed solution. The intraperitoneal solution must be infused within 24 hours after mixing. See section 4.2.
• Drugs should be added through the medication site in the larger chamber before opening the interchamber peel-seal. Drug compatibility must be checked before admixture and the pH and salts of the solution must be taken into account. The product should be used immediately after any drug addition.
• Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
• In the case of damage, the container should be discarded.
• The solution is free from bacterial endotoxins.
